Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by MyKnighton Jun 09, 2019 7:57am
176 Views
Post# 29809676

crohn patent on the 29 may

crohn patent on the 29 mayNot sure of all the medical implication but wondering if this could be bigger then GVHD?
Iknow that the market for ctohn is over a billions a year world wide....

Talking about the may  29 patent submission
But not sure how they work together....
For example, a combination of CBD and indole resulted in a 50-fold increase in AhR activation after only 8 hours of treatment. Furthermore, a combination of CBD and one or more of the Microbiome Metabolites completely blocked epithelial leakage, as measured by the electrical resistance of the epithelial barrier. This large effect underscores the significant role that CBD and these Microbiome Metabolites may play in repair of epithelial barrier damage.


I believe they discover this while they we re testing for gvhd.... how are they related , wondering if anybody with medical expertise can clarify this.....
Bullboard Posts